Enhancing cerebral vasculature analysis with pathlength-corrected 2D angiographic parametric imaging: A feasibility study

BACKGROUND

2D angiographic parametric imaging (API) quantitatively extracts imaging biomarkers related to contrast flow and is conventionally applied to 2D digitally subtracted angiograms (DSA's). In the interventional suite, API is typically performed using 1-2 projection views and is limited by vessel overlap, foreshortening, and depth-integration of contrast motion.

PURPOSE

This work explores the use of a pathlength-correction metric to overcome the limitations of 2D-API: the primary objective was to study the effect of converting 3D contrast flow to projected contrast flow using a simulated angiographic framework created with computational fluid dynamics (CFD) simulations, thereby removing acquisition variability.

METHODS

The pathlength-correction framework was applied to in-silico angiograms, generating a reference (i.e., ground-truth) volumetric contrast distribution in four patient-specific intracranial aneurysm geometries. Biplane projections of contrast flow were created from the reference volumetric contrast distributions, assuming a cone-beam geometry. A Parker-weighted reconstruction was performed to obtain a binary representation of the vessel structure in 3D. Standard ray tracing techniques were then used to track the intersection of a ray from the focal spot with each voxel of the reconstructed vessel wall to a pixel in the detector plane. The lengths of each ray through the 3D vessel lumen were then projected along each ray-path to create a pathlength-correction map, where the pixel intensity in the detector plane corresponds to the vessel width along each source-detector ray. By dividing the projection sequences with this correction map, 2D pathlength-corrected in-silico angiograms were obtained. We then performed voxel-wise (3D) API on the ground-truth contrast distribution and compared it to pixel-wise (2D) API, both with and without pathlength correction for each biplane view. The percentage difference (PD) between the resultant API biomarkers in each dataset were calculated within the aneurysm region of interest (ROI).

RESULTS

Intensity-based API parameters, such as the area under the curve (AUC) and peak height (PH), exhibited notable changes in magnitude and spatial distribution following pathlength correction: these now accurately represent conservation of mass of injected contrast media within each arterial geometry and accurately reflect regions of stagnation and recirculation in each aneurysm ROI. Improved agreement was observed between these biomarkers in the pathlength-corrected biplane maps: the maximum PD within the aneurysm ROI is 3.3% with pathlength correction and 47.7% without pathlength correction. As expected, improved agreement with ROI-averaged ground-truth 3D counterparts was observed for all aneurysm geometries, particularly large aneurysms: the maximum PD for both AUC and PH was 5.8%. Temporal parameters (mean transit time, MTT, time-to-peak, TTP, time-to-arrival, TTA) remained unaffected after pathlength correction.

CONCLUSIONS

This study indicates that the values of intensity-based API parameters obtained with conventional 2D-API, without pathlength correction, are highly dependent on the projection orientation, and uncorrected API should be avoided for hemodynamic analysis. The proposed metric can standardize 2D API-derived biomarkers independent of projection orientation, potentially improving the diagnostic value of all acquired 2D-DSA's. Integration of a pathlength correction map into the imaging process can allow for improved interpretation of biomarkers in 2D space, which may lead to improved diagnostic accuracy during procedures involving the cerebral vasculature.

Affective Contributions to Instrumental and Reactive Aggression in Middle Childhood: Variable- and Person-Centered Approaches

OBJECTIVE

Research on the role of affect in childhood aggression motives has largely focused on domain-level affective traits. Lower-order affective facets may show more distinct relationships with instrumental and reactive aggression - at both the variable and individual levels - and offer unique insights into whether and how several forms of affect are involved in aggression motives.

METHOD

Caregivers (98% mothers) of 342 children (Mage = 9.81 years, 182 girls, 31% White) reported on children's aggression and affect-relevant personality traits, personality pathology, and callous-unemotional traits.

RESULTS

Both reactive and instrumental aggressions were characterized by higher levels of trait irritability, fear, withdrawal, sadness, and callous-unemotional traits in zero-order analyses. Instrumental aggression was characterized by low trait positive emotions. Reactive aggression was uniquely associated with irritability, fear, withdrawal, and sadness, whereas instrumental aggression was uniquely associated with callous-unemotional traits and (low) positive emotions. Groups identified by latent profile analyses were differentiated only by aggression severity.

CONCLUSIONS

The findings support both the similarity and distinction of reactive and instrumental aggression vis-à-vis their affective phenomenology. Consistent with existing theories, reactive aggression was linked to multiple forms of negative emotionality, whereas instrumental aggression was linked to higher levels of callous-unemotional traits. In a novel finding, instrumental aggression was uniquely characterized by lower positive emotions. The findings highlight the utility of pre-registered approaches employing comprehensive personality-based affective frameworks to organize and understand similarities and differences between aggression functions.

Application of 1,000 fps High-Speed Angiography to In-Vitro Hemodynamic Evaluation of Left Ventricular Assist Device Outflow Graft Configurations

Left ventricular assist device (LVAD)-induced hemodynamics are characterized by fast-moving flow with large variations in velocity, making quantitative assessments difficult with existing imaging methods. This study demonstrates the ability of 1,000 fps high-speed angiography (HSA) to quantify the effect of the surgical implantation angle of a LVAD outflow graft on the hemodynamics within the ascending aorta in vitro . High-speed angiography was performed on patient-derived, three-dimensional-printed optically opaque aortic models using a nonsoluble contrast media, ethiodol, as a flow tracer. Outflow graft configuration angles of 45° and 90° with respect to the central aortic axis were considered. Projected velocity distributions were calculated from the high-speed experimental sequences using two methods: a physics-based optical flow algorithm and tracking of radio-opaque particles. Particle trajectories were also used to evaluate accumulated shear stress. Results were then compared with computational fluid dynamics (CFD) simulations to confirm the results of the high-speed imaging method. Flow patterns derived from HSA coincided with the impingement regions and recirculation zones formed in the aortic root as seen in the CFD for both graft configurations. Compared with the 45° graft, the 90° configuration resulted in 81% higher two-dimensional-projected velocities (over 100 cm/s) along the contralateral wall of the aorta. Both graft configurations suggest elevated accumulated shear stresses along individual trajectories. Compared with CFD simulations, HSA successfully characterized the fast-moving flow and hemodynamics in each LVAD graft configuration in vitro , demonstrating the potential utility of this technology as a quantitative imaging modality.

Angiographic velocimetry analysis using contrast dilution gradient method with a 1000 frames per second photon-counting detector

Purpose

Contrast dilution gradient (CDG) analysis is a quantitative method allowing blood velocity estimation using angiographic acquisitions. Currently, CDG is restricted to peripheral vasculature due to the suboptimal temporal resolution of current imaging systems. We investigate extension of CDG methods to the flow conditions of proximal vasculature using 1000 frames per second (fps) high-speed angiographic (HSA) imaging.

Approach

We performed in-vitro HSA acquisitions using the XC-Actaeon detector and 3D-printed patient-specific phantoms. The CDG approach was used for blood velocity estimation expressed as the ratio of temporal and spatial contrast gradients. The gradients were extracted from 2D contrast intensity maps synthesized by plotting intensity profiles along the arterial centerline at each frame. In-vitro results obtained at various frame rates via temporal binning of 1000 fps data were retrospectively compared to computational fluid dynamics (CFD) velocimetry. Full-vessel velocity distributions were estimated at 1000 fps via parallel line expansion of the arterial centerline analysis.

Results

Using HSA, the CDG method displayed agreement with CFD at or above 250 fps [mean-absolute error (MAE): 2.6±6.3  cm/s, p=0.05]. Relative velocity distributions correlated well with CFD at 1000 fps with universal underapproximation due to effects of pulsatile contrast injection (MAE: 4.3 cm/s).

Conclusions

Using 1000 fps HSA, CDG-based extraction of velocities across large arteries is possible. The method is sensitive to noise; however, image processing techniques and a contrast injection, which adequately fills the vessel assist algorithm accuracy. The CDG method provides high resolution quantitative information for rapidly transient flow patterns observed in arterial circulation.

Determining 3D Distributions of Pulsatile Blood Flow Using Orthogonal Simultaneous Biplane High-Speed Angiography (SB-HSA) with 1000 fps CdTe Photon Counting Detectors for 3D X-ray Particle Image Velocimetry (3D-XPIV) compared to Results Using Computational Fluid Dynamics (CFD)

3D hemodynamic distributions are useful for the diagnosis and treatment of aneurysms. Detailed blood-flow patterns and derived velocity maps can be obtained using 1000 fps High Speed Angiography (HSA). The novel orthogonal Simultaneous Biplane High-Speed Angiography (SB-HSA) system enables flow information to be quantified in multiple planes, and with additional components of flow at depth, accurate 3D flow distributions are available. Computational Fluid Dynamics (CFD) is the current standard for derivation of volumetric flow distributions, but obtaining solution convergence is computationally expensive and time intensive. More importantly, matching in-vivo boundary conditions is non-trivial. Therefore, an experimentally derived 3D flow distribution method could offer realistic results with less computation time. Using SB-HSA image sequences, 3D X-Ray Particle Image Velocimetry (3D-XPIV) was explored as a new method for assessing 3D flow. 3D-XPIV was demonstrated using an in-vitro setup, where a patient-specific internal carotid artery aneurysm model was attached to a flow loop, and an automated injection of iodinated microspheres was used as a flow tracer. Two 1000 fps photon-counting detectors were placed orthogonally with the aneurysm model in the FOV of both planes. Frame-synchronization of the two detectors made correlation of single-particle velocity components at a given timepoint possible. With frame-rates of 1000 fps, small particle displacements between frames resolved realistic time varying flow, where accurate velocity distributions depended on near-instantaneous velocities. 3D-XPIV velocity distributions were compared to CFD velocity distributions, where the simulation boundary conditions matched the in-vitro setup. Results showed similar velocity distributions between CFD and 3D-XPIV.

Multi-angled simultaneous biplane High-Speed Angiography (HSA) of patient-specific 3D-printed aneurysm phantoms using 1000 fps CdTe Photon-Counting Detectors (PCD's)

1000 fps HSA enables visualization of flow details, which may be important in accurately guiding interventional procedures; however, single-plane imaging may lack clear visualization of vessel geometry and flow detail. The previously presented high-speed orthogonal biplane imaging may overcome these limitations but may still result in foreshortening of vessel morphology. In certain morphologies, acquiring two non-orthogonal biplane projections at multiple angles can provide better flow detail rather than a standard orthogonal biplane acquisition. Flow studies of aneurysm models were performed, where simultaneous biplane acquisitions at various angles separating the two detector views allowed for better evaluation of morphology and flow. 3D-printed, patient-specific internal carotid artery aneurysm models were imaged with various non-orthogonal angles between the two high-speed photon-counting detectors (7.5 cm x 5 cm FOV) to provide frame-correlated simultaneous 1000-fps image sequences. Fluid dynamics were visualized in multi-angled planes of each model using automated injections of iodine contrast media. The resulting dual simultaneous frame-correlated 1000-fps acquisitions from multiple planes of each aneurysm model provided improved visualization of complex aneurysm geometries and flow streamlines. Multi-angled biplane acquisitions with frame correlation allows for further understanding of aneurysm morphology and flow details: additionally, the ability to recover fluid dynamics at depth enables accurate analysis of 3D flow streamlines, and it is expected that multiple-planar views will enable better volumetric flow visualization and quantification. Such better visualization has the potential to improve interventional procedures.

Use of high-speed angiography HSA-derived boundary conditions and Physics Informed Neural Networks (PINNs) for comprehensive estimation of neurovascular hemodynamics

Purpose

Physics-informed neural networks (PINNs) and computational fluid dynamics (CFD) have both demonstrated an ability to derive accurate hemodynamics if boundary conditions (BCs) are known. Unfortunately, patient-specific BCs are often unknown, and assumptions based upon previous investigations are used instead. High speed angiography (HSA) may allow extraction of these BCs due to the high temporal fidelity of the modality. We propose to investigate whether PINNs using convection and Navier-Stokes equations with BCs derived from HSA data may allow for extraction of accurate hemodynamics in the vasculature.

Materials and Methods

Imaging data generated from in vitro 1000 fps HSA, as well as simulated 1000 fps angiograms generated using CFD were utilized for this study. Calculations were performed on a 3D lattice comprised of 2D projections temporally stacked over the angiographic sequence. A PINN based on an objective function comprised of the Navier-Stokes equation, the convection equation, and angiography-based BCs was used for estimation of velocity, pressure and contrast flow at every point in the lattice.

Results

Imaging-based PINNs show an ability to capture such hemodynamic phenomena as vortices in aneurysms and regions of rapid transience, such as outlet vessel blood flow within a carotid artery bifurcation phantom. These networks work best with small solution spaces and high temporal resolution of the input angiographic data, meaning HSA image sequences represent an ideal medium for such solution spaces.

Conclusions

The study shows the feasibility of obtaining patient-specific velocity and pressure fields using an assumption-free data driven approach based purely on governing physical equations and imaging data.

2D versus 3D comparison of angiographic imaging biomarkers using computational fluid dynamics simulations of contrast injections

Quantitative angiography (QAngio) may provide hemodynamic information during neurointerventional procedures through imaging biomarkers related to contrast flow. The standard clinical implementation of QAngio is limited by projection imaging: analysis of contrast motion within complex 3D geometries is restricted to 1-2 projection views, truncating the potential wealth of imaging biomarkers related to disease progression or efficacy of treatment. To understand the limitations of 2D biomarkers, we propose the use of in-silico contrast distributions to investigate the potential benefits of 3D-QAngio within the context of neurovascular hemodynamics. Ground-truth in-silico contrast distributions were generated in two patient-specific intracranial aneurysm models, accounting for the physical interactions of contrast media and blood. A short bolus of contrast was utilized to obtain full a wash-in/ wash-out cycle within the aneurysm ROI. Simulated angiograms mimicking clinical cone-beam CT (CBCT) acquisitions were then generated, and volumetric contrast distributions were reconstructed to analyze bulk contrast flow. The ground-truth 3D-CFD, reconstructed 3D-CBCT-DSA, and 2D-DSA projections were used to extract QAngio parameters related to contrast time dilution curves, such as area under the curve (AUC), peak height (PH), mean-transit-time (MTT), time-to-peak (TTP), and time to arrival (TTA). An initial comparison of quantitative flow parameters in both 2D and 3D, in a smaller and larger aneurysm, indicated that 3D-QAngio can provide a good description of bulk flow characteristics (TTA, TTP, MTT), but recovery of integral parameters (PH, AUC) aneurysms is limited. Nonetheless, incorporation of 3D-QAngio methods may provide additional insight into our understanding of abnormal vascular flow patterns.

Comparison of pulsatile flow dynamics before and after endovascular intervention in 3D-printed patient-specific internal carotid artery aneurysm models using 1000 fps photon-counting detectors for Simultaneous Biplane High Speed Angiography (SB-HSA)

A significant challenge regarding the treatment of aneurysms is the variability in morphology and analysis of abnormal flow. With conventional DSA, low frame rates limit the flow information available to clinicians at the time of the vascular intervention. With 1000 fps High-Speed Angiography (HSA), high frame rates enable flow details to be better resolved for endovascular interventional guidance. The purpose of this work is to demonstrate how 1000 fps biplane-HSA can be used to differentiate flow features, such as vortex formation and endoleaks, amongst patient-specific internal carotid artery aneurysm phantoms pre- and post-endovascular intervention using an in-vitro flow setup. The aneurysm phantoms were attached to a flow loop configured to a carotid waveform, with automated injections of contrast media. Simultaneous Biplane High-Speed Angiographic (SB- HSA) acquisitions were obtained at 1000 fps using two photon-counting detectors with the respective aneurysm and inflow/ outflow vasculature in the FOV. After x-rays were turned on, the detector acquisitions occurred simultaneously, during which iodine contrast was injected at a continuous rate. A pipeline stent was then deployed to divert flow from the aneurysm, and image sequences were once again acquired using the same parameters. Optical Flow, an algorithm that calculates velocity based on spatial-temporal intensity changes between pixels, was used to derive velocity distributions from HSA image sequences. Both the image sequences and velocity distributions indicate detailed changes in flow features amongst the aneurysms before and after deployment of the interventional device. SB-HSA can provide detailed flow analysis, including streamline and velocity changes, which may be beneficial for interventional guidance.

Investigating Angiographic Injection Parameters for Cerebral Aneurysm Hemodynamic Characterization Using Patient-Specific Simulated Angiograms

Cerebral aneurysm (CA) rupture is one of the major causes of hemorrhagic stroke. During endovascular therapy (ET), neurointerventionalists rely on qualitative image sequences and do not have access to crucial quantitative hemodynamic information. Quantifying angiographic image sequences can provide vital information, but it is not possible to perform this in a controlled manner in vivo. Computational fluid dynamics (CFD) is a valuable tool capable of providing high fidelity quantitative data by replicating the blood flow physics within the cerebrovasculature. In this work, we use simulated angiograms (SA) to quantify the hemodynamic interaction with a clinically utilized contrast agent. SA enables extraction of time density curves (TDC) within the desired region of interest to analyze hemodynamic parameters such as time to peak (TTP) and mean transit time (MTT) within the aneurysm. We present on the quantification of several hemodynamic parameters of interest for multiple, clinically-relevant scenarios such as variable contrast injection duration and bolus volumes for 7 patient-specific CA geometries. Results indicate that utilizing these analyses provides valuable hemodynamic information relating vascular and aneurysm morphology, contrast flow conditions and injection variability. The injected contrast circulates for multiple cardiac cycles within the aneurysmal region, especially for larger aneurysms and tortuous vasculature. The SA approach enables determination of angiographic parameters for each scenario. Together, these have the potential to overcome the existing barriers in quantifying angiographic procedures in vitro or in vivo, and can provide clinically valuable hemodynamic insights for CA treatment.

Geometrically independent contrast dilution gradient (CDG) velocimetry using photon-counting 1000 fps High Speed Angiography (HSA) for 2D velocity distribution estimation

Purpose

Previous studies have demonstrated the efficacy of contrast dilution gradient (CDG) analysis in determining large vessel velocity distributions from 1000 fps high-speed angiography (HSA). However, the method required vessel centerline extraction, which made it applicable only to non-tortuous geometries using a highly specific contrast injection technique. This study seeks to remove the need for a priori knowledge regarding the direction of flow and modify the vessel sampling method to make the algorithm more robust to non-linear geometries.

Materials and Methods

1000 fps HSA acquisitions were obtained in vitro with a benchtop flow loop using the XC-Actaeon (Varex Inc.) photon-counting detector, and in silico using a passive-scalar transport model within a computational fluid dynamics (CFD) simulation. CDG analyses were obtained using gridline sampling across the vessel, and subsequent 1D velocity measurement in both the x- and y-directions. The velocity magnitudes derived from the component CDG velocity vectors were aligned with CFD results via co-registration of the resulting velocity maps and compared using mean absolute percent error (MAPE) between pixels values in each method after temporal averaging of the 1-ms velocity distributions.

Results

Regions well-saturated with contrast throughout the acquisition showed agreement when compared to CFD (MAPE of 18% for the carotid bifurcation inlet and MAPE of 27% for the internal carotid aneurysm), with respective completion times of 137 seconds and 5.8 seconds.

Conclusions

CDG may be used to obtain velocity distributions in and surrounding vascular pathologies provided the contrast injection is sufficient to provide a gradient, and diffusion of contrast through the system is negligible.

Semi-automatic Co-Registration of 3D CFD Vascular Geometry to 1000 FPS High-Speed Angiographic (HSA) Projection Images for Flow Determination Comparisons

Image co-registration is an important tool that is commonly used to quantitatively or qualitatively compare information from images or data sets that vary in time, origin, etc. This research proposes a method for the semi-automatic co-registration of the 3D vascular geometry of an intracranial aneurysm to novel high-speed angiographic (HSA) 1000 fps projection images. Using the software Tecplot 360, 3D velocimetry data generated from computational fluid dynamics (CFD) for patient-specific vasculature models can be extracted and uploaded into Python. Dilation, translation, and angular rotation of the 3D velocimetry data can then be performed in order to co-register its geometry to corresponding 2D HSA projection images of the 3D printed vascular model. Once the 3D CFD velocimetry data is geometrically aligned, a 2D velocimetry plot can be generated and the Sørensen-Dice coefficient can be calculated in order to determine the success of the co-registration process. The co-registration process was performed ten times for two different vascular models and had an average Sørensen-Dice coefficient of 0.84 ± 0.02. The method presented in this research allows for a direct comparison between 3D CFD velocimetry data and in-vitro 2D velocimetry methods. From the 3D CFD, we can compare various flow characteristics in addition to velocimetry data with HSA-derived flow metrics. The method is robust to other vascular geometries as well.

Use of 1000fps High Speed X-ray Angiography (HSAngio) to quantify differences in flow diversion effects of three stents with different coverage densities in a cerebral aneurysm invitro model

High temporal resolution images acquired using 1000fps HSAngio can be used to visualize blood flow patterns and derive flow velocities during neurointerventional procedures. In this work we use this technology to quantify the changes in the blood flow velocities inside a cerebral aneurysm after treatment with three different stents with varying degrees of metal coverage density; stent A : <2%, stent B: 23% and stent C: 40%. A 3D printed in-vitro model of internal carotid artery aneurysm was connected to a flow loop (60% water, 40% glycerol solution used as circulation fluid, circulation flow rate 8 L/s). An automatic programmable injector (KD Scientific Legato 110) was used to inject iodine contrast agent at a rate of 88 mL/min in 3secs. 1000 fps HSAngio sequences of the contrast injection were acquired using an Aries single photon counting detector (Direct Conversion Inc., Stockholm). From these images blood flow velocities were calculated using an optical flow algorithm. As expected the biggest reduction in blood flow velocity inside the aneurysm was 32.4% after deployment of stent C. However, the velocity profile distribution indicated there was still a significant inflow jet into the aneurysm which could be caused by a endoluminal leak between the stent and the vessel wall. The average reduction was only 14% after placement of stent B and 3% after placement of stent A. Blood velocity distribution maps derived using 1000fps HSAngiography technology can be used to evaluate the quality of flow diversion within the aneurysm after placement of stent. Critical information such as endo luminal leakage which can cause treatment failure can also be detected.

Simultaneous Biplane High Speed 1000 fps X-ray Angiography (HSAngio)

High-speed 1000-fps x-ray Angiography (HSAngio) images can be used to visualize blood-flow patterns and derive flow velocities during neurointerventional procedures. In this work, we present for the very first-time, orthogonal views of contrast injection in an aneurysm model acquired simultaneously using biplane HSAngio imaging. 3-D printed in-vitro models A and B of two different internal carotid-artery aneurysms were connected to a flow loop (circulation fluid: 60% water, 40% glycerol solution, circulation flow rate: 8 L/s). An automatic programmable injector (KD Scientific Legato 110) injected iodine contrast agent at a rate of 88 mL/min for a duration of 3 sec. With an RQA5 spectrum, 1000 fps HSAngio sequences of the contrast injection were acquired simultaneously on the frontal plane using the Actaeon detector (Direct Conversion, Stockholm) and on the lateral plane using the Aries (Direct Conversion, Stockholm) detector. The start of contrast injection and simultaneous biplane x-ray exposures and detector image acquisitions were manually synchronized to capture the initial inflow of contrast into the aneurysm region. For model A the frontal plane images gave a better visualization of the flow streamlines in the parent artery in the inflow (average velocity 28 cm/s) and outflow (average velocity 24 cm/s) region of the aneurysm. The vortices within the aneurysm region especially within the aneurysm dome were better visualized in the lateral plane images (average velocity 27 cm/s). Biplane HSAngio imaging techniques can give more accurate representations of 3-D blood flow within the complex vascular pathology of the human brain, compared to single-plane imaging.

Derivation of vascular wall shear stress from 1000 fps high-speed angiography (HSA) velocity distributions

Pathological changes in blood flow lead to altered hemodynamic forces, which are responsible for a number of conditions related to the remodeling and regeneration of the vasculature. More specifically, wall shear stress (WSS) has been shown to be a significant hemodynamic parameter with respect to aneurysm growth and rupture, as well as plaque activation leading to increased risk of stroke. In-vivo measurement of shear stress is difficult due to the stringent requirements on spatial resolution near the wall boundaries, as well as the deviation from the commonly assumed parabolic flow behavior at the wall. In this work, we propose an experimental method of in-vitro WSS calculations from high-temporal resolution velocity distributions, which are derived from 1000 fps high-speed angiography (HSA). The high-spatial and temporal resolution of our HSA detector makes such high-resolution velocity gradient measurements feasible. Presented here is the methodology for calculation of WSS in the imaging plane, as well as initial results for a variety of vascular geometries at physiologically realistic flow rates. Further, the effect of spatial resolution on the gradient calculation is explored using CFD-derived velocity data. Such angiographic-based analysis with HSA has the potential to provide critical hemodynamic feedback in an interventional setting, with the overarching objective of supporting clinical decision-making and improving patient outcomes.

Initial evaluation of 2D and 3D simulated high-speed 1000 fps vascular contrast-flow image sequences using computational fluid dynamics (CFD)

Digital subtraction angiography (DSA) remains the clinical standard for detailed visualization of the neurovasculature due to its high-spatial resolution; however, detailed blood-flow quantification is impaired by its low-temporal resolution. Advances in photon-counting detector technology have led us to develop High-Speed Angiography (HSA), where x-ray images are acquired at 1000 fps for more accurate visualization and quantification of blood flow. We have implemented a physics-based optical flow method to extract such information from HSA, but validation of the angiography-derived velocity distributions is not straightforward. Computational fluid dynamics (CFD) is widely regarded as the benchmark for hemodynamic analysis, as it provides a multitude of quantitative flow parameters throughout the volume of interest. However, there are several limitations with this method related to over-simplification of boundary conditions and suboptimal meshing (spatial resolution), that make CFD simulation results an inexact criterion for validation. To overcome this issue for HSA validation, CFD was used to generate both simulated high-speed angiograms and the corresponding ground-truth 3D flow fields to better understand the relationship between the 3D volumetric-flow distribution and the 2D projected-flow distribution as is obtained with angiography, and the subsequent 2D approximation of flow velocity. Several geometries were investigated, ranging from simple pipe models to complex patient-specific aneurysms. Simulated datasets were analyzed with the optical flow algorithm, and the effects of flow divergence, quantum mottle, and intensity gradient on the calculation were evaluated. From these simulations, we can evaluate whether flow fields reconstructed from HSA are representative of significant flow patterns in the 3D vasculature.

Initial investigations of scatter cross-talk in simultaneous biplane high-speed 1000 frames per second neuro-angiography using Monte Carlo simulations

The Aries photon counting detector (PCD) by Direct Conversion Inc. can image up to 1000 frames per second and is used to track contrast bolus in neuro-vasculature for hemodynamic calculations. For 3D tracking, synchronized biplane imaging with 1 ms acquisition times is used such that both imaging planes are exposed simultaneously. This leads to cross-scattered radiation being detected and a degradation of image quality compared to single-plane imaging. In this study, we utilize Monte Carlo (MC) methods to quantify the increase in scatter due to cross-talk without the use of a radiographic grid. EGSnrc biplane simulations were performed with the Zubal anthropomorphic head phantom. The total scatter plus primary and cross-scatter was calculated in the imaging planes for two orthogonal AP and lateral beams with a field size consistent with the 7.5×5 cm Aries detector, while the primary was determined with a 1×1 mm beam. The forward scatter was then determined from the difference between total and primary. The scatter is seen to increase by 4%-56% for AP projections and 48%-71% for lateral projections depending on detector orientation during simultaneous exposure. Scatter degradation from cross-talk can be reduced using an anti-scatter grid as well as the energy thresholding capabilities of the Aries PCD.

Comparison of quantitative imaging characteristics between a new, larger-FOV 1000 fps high-speed angiographic (HSA) photon-counting detector (Aries) with a smaller HSA detector (Actaeon)

High Speed Angiography (HSA) requires imaging detectors with both high-temporal and high-spatial resolution. Both the Aries and Acteon detectors by Direct Conversion (Stockholm, Sweden) are CdTe direct photon-counting detectors (PCD) that have acquisition frame rates of up to 1000-fps and a 100-micrometer pixel pitch; however, the new Aries detector offers a larger field of view (512 × 768 pixels) compared to the smaller Actaeon detector (256 × 256 pixels). An expanded field of view is required for imaging of larger vasculature, thus the Aries offers this advantage. Evaluations were performed of both detectors under Anti-Coincidence Circuitry (ACC-ON) mode, which corrects for charge sharing between pixels. Initial evaluations of instrumentation noise and detector energy-threshold calibration using Am-241 gamma spectroscopy were performed for the new Aries detector. Linearity was also evaluated for the Aries for each of the 12 individual modules that compose the detector field to check for homogeneity in response to exposure throughout the detector. Finally, Normalized Noise Power Spectrum (NNPS), Modulation Transfer Function (MTF) and Detective Quantum Efficiency (DQE) were then compared between the Aries and Actaeon detectors at two different exposures and detector energy thresholds. The detectors are linear up to approximately 1000 μR and have no instrumentation noise above a threshold of 15 keV. As expected, the MTF's and DQE's are similar between the Aries and Actaeon detectors, and there are thus no tradeoff's in image quality to achieve the larger FOV.

2D vessel contrast dilution gradient (CDG) analysis using 1000 fps high speed angiography (HSA) for velocity distribution estimation

PURPOSE

Contrast dilution gradient (CDG) analysis is a technique used to extract velocimetric 2D information from digitally subtracted angiographic (DSA) acquisitions. This information may then be used by clinicians to quantitatively assess the effects of endovascular treatment on flow conditions surrounding pathologies of interest. The method assumes negligible diffusion conditions, making 1000 fps high speed angiography (HSA), in which diffusion between 1 ms frames may be neglected, a strong candidate for velocimetric analysis using CDG. Previous studies have demonstrated the success of CDG analysis in obtaining velocimetric one-dimensional data at the arterial centerline of simple vasculature. This study seeks to resolve velocity distributions across the entire vessel using 2D-CDG analysis with HSA acquisitions.

MATERIALS AND METHODS

HSA acquisitions for this study were obtained in vitro with a benchtop flow loop at 1000 fps using the XC-Actaeon (Direct Conversion Inc.) photon counting detector. 2D-CDG analyses were compared with computational fluid dynamics (CFD) via automatic co-registration of the results from each velocimetry method. This comparison was performed using mean absolute error between pixel values in each method (after temporal averaging).

RESULTS

CDG velocity magnitudes were slightly under approximated relative to CFD results (mean velocity: 27 cm/s, mean absolute error: 4.3 cm/s) as a result of incomplete contrast filling. Relative 2D spatial velocity distributions in CDG analysis agreed well with CFD distributions qualitatively.

CONCLUSIONS

CDG may be used to obtain velocity distributions in and surrounding vascular pathologies provided diffusion is negligible relative to convection in the flow, given a continuous gradient of contrast.

Leveraging Patient-Specific Simulated Angiograms to Characterize Cerebral Aneurysm Hemodynamics using Computational Fluid Dynamics

Cerebral aneurysms (CA) affect nearly 6% of the US population and its rupture is one of the major causes of hemorrhagic stroke. Neurointerventionalists performing endovascular therapy (ET) to treat CA rely on qualitative image sequences obtained under fluoroscopy guidance alone, and do not have access to crucial quantitative information regarding blood flow before, during and after treatment - partially contributing to a failure rate of up to 30%. Computational fluid dynamics (CFD) is a powerful tool that can provide a wealth of quantitative data; however, CFD has found limited utility in the clinic due to the challenges in obtaining hemodynamic boundary conditions for each patient. In this work, we present a novel CFD-based simulated angiogram approach (SAA) that resolves the blood flow physics and interaction between blood and injected contrast agent to extract quantitative hemodynamic parameters which can be used to design real-time parametric imaging analysis. The SAA enables correlating contrast agent transport to the underlying hemodynamic conditions via time-density curves (TDC) obtained at several points in the region of interest. The ability of the TDC and the SAA to provide critical hemodynamic parameters in and around CA anatomies, such as washout and local flow changes is explored and presented. This provides invaluable quantitative data to the clinician at the time of intervention, since it incorporates the physics of blood flow and correlates the contrast transport to hemodynamic parameters quantitatively - thereby enabling the clinician to take informed decisions that improve treatment outcomes.

Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)☆

BACKGROUND

In colon cancer, tumor deposits (TD) are considered in assigning prognosis and staging only in the absence of lymph node metastasis (i.e. stage III pN1c tumors). We aimed to evaluate the prognostic value of the presence and the number of TD in patients with stage III, node-positive colon cancer.

PATIENTS AND METHODS

All participants from the CALGB/SWOG 80702 phase III trial were included in this post hoc analysis. Pathology reports were reviewed for the presence and the number of TD, lymphovascular and perineural invasion. Associations with disease-free survival (DFS) and overall survival (OS) were evaluated by multivariable Cox models adjusting for sex, treatment arm, T-stage, N-stage, lymphovascular invasion, perineural invasion and lymph node ratio.

RESULTS

Overall, 2028 patients were included with 524 (26%) TD-positive and 1504 (74%) TD-negative tumors. Of the TD-positive patients, 80 (15.4%) were node negative (i.e. pN1c), 239 (46.1%) were pN1a/b (<4 positive lymph nodes) and 200 (38.5%) were pN2 (≥4 positive lymph nodes). The presence of TD was associated with poorer DFS [adjusted hazard ratio (aHR) = 1.63, 95% CI 1.33-1.98] and OS (aHR = 1.59, 95% CI 1.24-2.04). The negative effect of TD was observed for both pN1a/b and pN2 groups. Among TD-positive patients, the number of TD had a linear negative effect on DFS and OS. Combining TD and the number of lymph node metastases, 104 of 1470 (7.1%) pN1 patients were re-staged as pN2, with worse outcomes than patients confirmed as pN1 (3-year DFS rate: 65.4% versus 80.5%, P = 0.0003; 5-year OS rate: 87.9% versus 69.1%, P = <0.0001). DFS was not different between patients re-staged as pN2 and those initially staged as pN2 (3-year DFS rate: 65.4% versus 62.3%, P = 0.4895).

CONCLUSION

Combining the number of TD and the number of lymph node metastases improved the prognostication accuracy of tumor-node-metastasis (TNM) staging.

Evaluation of methods to derive blood flow velocity from 1000 fps high-speed angiographic sequences (HSA) using optical flow (OF) and computational fluid dynamics (CFD)

Digital Subtraction Angiography (DSA) is considered the gold standard for imaging and guiding treatment of neurovascular lesions, such as cerebral aneurysms and carotid stenoses. Though DSA can show high-resolution morphology, it remains difficult to extract temporal physiological information, because higher frame-rates are necessary to accurately quantify neurovascular flow details. Recent advances in photon-counting detector technology have led us to develop High-Speed Angiography (HSA), where X-ray images are acquired at 1000 fps for more accurate visualization and quantification of blood flow. Blood flow was imaged using HSA under constant flow conditions within various 3D printed patient-specific phantoms. Blood velocity was quantified using an open source Optical Flow algorithm, OpenOpticalFlow, to perform velocity estimation based on the spatio-temporal intensity changes of iodinated contrast wavefronts. The results of these algorithms are then compared with Computational Fluid Dynamics (CFD) simulations, using the same inlet boundary conditions and model geometries. The performance of these algorithms at lower temporal resolution was then also assessed by simulating lower frame rates from the acquired 1000 fps data. It is important to ascertain the hemodynamic effect of abnormal neurovascular conditions, as well as their effect on treatment of such conditions during the actual clinical interventional procedure. While theoretical CFD results requiring considerable computer capability are delayed for hours or more, it is expected that clinical results from multiple HSA sequences will be available almost immediately while the patient is still under treatment, and even right after flow conditions are changed beneficially by the intervention.

Characterization of velocity patterns produced by pulsatile and constant flows using 1000 fps high-speed angiography (HSA)

In order to accurately quantify rapidly changing blood flow velocities, as typically seen in the neurovasculature, high temporal resolution is necessary. Current methods to extract velocity data from angiographic image sequences are generally limited to 30 fps or less. High-speed angiography (HSA) with a maximal frame rate of 1000 fps can be used to evaluate time-dependent flow details normally averaged out with lower frame rates. For new HSA image sequences, two different quantitative methods were utilized to extract high-temporal resolution velocity changes: X-Ray Particle Image Velocimetry (X-PIV) and optical flow (OF). A variety of flow conditions were examined in a range of patient-specific 3D-printed phantoms. Both pulsatile and constant flow settings were investigated. X-PIV was performed using radiopaque sub-millimeter microspheres, which were tracked throughout the image sequence to provide accurate, but limited sampling of the velocity field within the 3D-printed models. Also, an open source optical flow algorithm, OpenOpticalFlow, was used to perform velocity estimation based on the spatio-temporal intensity changes of iodinated contrast wavefronts. Periodic changes in velocity within each phantom ROI can be illustrated throughout the pulsatile cycle capture by the high-speed detector. In the constant flow sequences, changes in velocity across the phantom geometry can be seen. The ability to accurately measure detailed velocity distributions and velocity changes throughout various flow conditions at high temporal resolution enables further insight into the evaluation and treatment of neurovascular disease states.

Creating a personalized evaluation framework for patient-reported outcomes: an illustration using the EQ-5D visual analogue scale

BACKGROUND

This paper outlines the creation of an intuitive, personalized evaluation framework for Patient-Reported Outcomes, using the EQ-5D visual analog scale (VAS) as an illustration.

METHODS

A draft framework asked patients to divide and label the EQ-5D-VAS into different levels or categories of health. Comprehension of the framework and patient-defined health level labels, and how they map onto the EQ-5D-VAS, were tested through in-person, semi-structured interviews with individuals self-reporting cardiovascular disease. Interviews were conducted in three waves, with the framework revised between waves.

RESULTS

Analyses included 14 participants. Eight participants (57.1%) felt that four levels of health were appropriate and there was general agreement on the labels; Poor, Fair, Good, and Excellent. There was substantial variability in where patients drew lines to indicate the level boundaries; Poor ranged between 0 and 50; Fair 10-75; Good 40-91; Excellent 60-100. In wave 3, all participants demonstrated appropriate comprehension of the framework.

CONCLUSIONS

The framework was well understood. The wide range of margins and the extent of overlap between the levels provide strong evidence for the relevance of the personalized evaluation framework approach, and specifically a personalized EQ-5D-VAS evaluation framework, to better understand and interpret each individual's response to the item.

Improving Breast Cancer Survivors' Psychological Outcomes and Quality of Life: Alternatives to Traditional Psychotherapy

Purpose of Review

Breast cancer survivors (BCS) often experience psychological problems and lowered quality of life (QOL). While helpful, psychotherapy is often costly and inaccessible. This review aims to provide practitioners with the latest information on empirically tested interventions among BCS that may be used in lieu of, or in addition to, traditional psychotherapy.

Recent Findings

Recent developments in cancer-related psychological interventions include a focus on facilitating emotional disclosure (e.g., expressive writing), enhancing close relationships (e.g., couples-based interventions), and increasing feasibility and accessibility via online and computer-based intervention programs. These alternatives to psychotherapy offer a number of benefits including cost-effectiveness, personalized adaptability, and ease of implementation.

Summary

Utilizing these interventions as alternatives or supplements to traditional psychotherapy may offer BCS an opportunity to increase their QOL, improve psychosocial outcomes, and find meaning in their cancer experience. Choosing the appropriate intervention requires understanding the unique circumstances for each survivor and their family.

Abstract P5-01-02: Multimodality molecular imaging with dynamic 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and MRI to evaluate response and resistance to neoadjuvant chemotherapy (NAC)

Background: Using quantitative FDG PET to measure glucose metabolism and perfusion, and dynamic contrast-enhanced (DCE) MRI to measure perfusion, we previously identified a metabolic signature for breast cancer resistant to NAC. This imaging signature is (1) persistent or increased tumor perfusion despite treatment, (2) an altered pattern of glucose kinetics in response to therapy, and (3) pre-therapy mismatch between tumor metabolism (MRFDG) and glucose delivery (K1) (high ratio of MRFDG/K1). These patterns predict poor response, early relapse and death independent of established prognostic factors, including pathologic response. Identification of factors associated with resistance or response to therapy is the translational goal of "Quantitative Dynamic PET and MRI in Breast Cancer Therapy," part of the Seattle Breast SPORE (1P50CA138293).

Methods: Patients (Pts) undergoing NAC for histologically confirmed breast cancer (stage II-III) were approached for this trial (CCIRB# 7587). FDG PET and DCE-MRI were obtained pre-therapy, 2-12 weeks after start of NAC (mid-therapy) and after completion of NAC. Breast biopsies were obtained pre-therapy and post-NAC. FDG PET included a dynamic scan with kinetic analysis. PET measures included SUVmax, MRFDG, K1, Ki, and Patlak. 3T DCE-MRI measurements included semi-quantitative vascular parameters of peak enhancement (PE), signal enhancement ratio (SER), washout fraction, functional tumor volume, and apparent diffusion coefficient (ADC) from diffusion-weighted MRI (DWI). Breast biopsies were assayed by immunohistochemistry and gene expression profiling. NAC was per physician's choice with most pts receiving weekly paclitaxel (with trastuzumab if HER2+) followed by doxorubicin/cyclophosphamide.

Results: 32 pts have completed the study. Pathologic complete response (pCR), defined as absence of invasive cancer in the breast, was observed in 9 (28%); near pCR defined as only microscopic residual invasive cancer in 3 (9%) more pts. Mid-therapy decline in SUVmax and K1 was associated with near pCR; (p-value 0.06, 0.04, respectively). Pre-therapy PET measures of MRFDG and K1 were not predictive of pCR. On MRI, pre-therapy PE (p=0.009), SER (p=0.01), washout fraction (p=0.02), ADC (p=0.08, trend) and mid-therapy change in volume (p=0.05) were each predictive of pCR. Gene profiling of pre-therapy biopsies showed correlation between high MRFDG/K1 ratio in basal and luminal B tumors.

Conclusions: Assessment of serial changes in tumor metabolism and perfusion by FDG PET and DCE-MRI is feasible in the clinic. Mid-therapy decline in metabolism and glucose delivery was predictive of pCR; consistent with prior retrospective series. Baseline DCE-MRI and DWI measures show promise to predict response, and associations of mid-therapy change in MR functional tumor volume with pCR agree with findings of another multisite clinical trial (ISPY). These imaging parameters may serve as useful biomarkers to inform future neoadjuvant trials. Integration of imaging data with gene expression profiling revealed that the pattern of metabolism in luminal B tumors was closer to that of the basal subtype compared to other ER-positive tumors.

Citation Format: Specht JM, Partridge S, Chai X, Novakova A, Peterson L, Shields A, Guenthoer J, Linden HM, Gralow JR, Gadi V, Korde L, Hills D, Hsu L, Hockenbery DM, Kinahan P, Mankoff DA, Porter PL. Multimodality molecular imaging with dynamic 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and MRI to evaluate response and resistance to neoadjuvant chemotherapy (NAC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-01-02.

Abstract P4-01-03: HDACi (vorinostat) in metastatic breast cancer to restore sensitivity to ER-directed (AI) therapy: A phase II clinical trial with FES imaging correlates

Background: Histone deacetylase inhibitors (HDACi) have shown pre-clinical promise in estrogen receptor(ER)-modulation and restoring sensitivity to endocrine manipulation, suggesting potential clinical benefit (Sabnis 2011) (Huang 2000) in ER+ breast cancer. Vorinostat is an FDA-approved HDACi for CTCL, and could have a beneficial role in restoring ER-signaling in endocrine-resistant tumors (Munster 2011) (Yardley 2011). [F-18]fluoroestradiol (FES) PET imaging may be used to monitor regional tumor ER expression in patients with breast cancer (Linden 2011).

Methods: Patients with metastatic breast cancer with prior clinical benefit from endocrine manipulation who progressed on an AI therapy are eligible for this ongoing trial. In part A, patients were given vorinostat for 2 weeks, then resumed AI for 6 W. In part B (reflecting results of prior HDACi trials) patients are given vorinostat 400mg po daily 5/7 days 3/4 weeks while AI is given continuously. Paired FES and FDG PET are performed at baseline, week 2 and 8; clinical/radiologic assessment of disease is also performed at week 8. Patients with clinical benefit (response or stable disease) may continue on treatment until progressive disease or study withdrawal. Lesion-level analysis of the association between baseline FES uptake (logged) and FES/FDG ratio used generalized estimating equations (GEE) with small-sample adjustments to standard errors.

Results: 12/ 20 planned patients have accrued, and the treatment is well tolerated. Enrolled women were postmenopausal, the majority with primary infiltrating ductal tumors, bone/soft tissue dominant with longstanding metastatic disease, exposed to multiple endocrine and chemotherapy regimens. Five patients have had clinical benefit (2/4 on part B with greater HDACi exposure). One patient withdrew from the study due to toxicity. FES and FDG uptake was analyzed in 42 lesions in 11 patients. Average FES uptake was 2.0 (SULmean) for patients with clinical benefit, and 1.2 in patients with progressive disease by 8 weeks (p = 0.09). FES/FDG ratio at baseline was also associated with response (p = 0.04).

Conclusions: HDACi therapy is promising in relapsed ER+ breast cancer. Imaging of metabolic pathways in parallel with clinical trials may accelerate understanding of the underlying tumor biology and refine treatment selection.

Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-01-03.

Abstract P4-01-02: The role of FLT PET early assessment of response to endocrine therapy for early stage breast cancer

Background: In estrogen receptor positive (ER+) tumors, a low proliferative index (Ki-67) two weeks into endocrine therapy predicts response. FLT PET non-invasively measures tumor proliferation in vivo. The pre-operative window is an opportunity to assess impact of systemic therapies. We tested associations between FLT PET qualitative and quantitative measures and Ki-67 following two weeks of aromatase inhibitor (AI) therapy.

Methods: Women with clinical stage I-II ER+ HER2– breast cancer underwent “run-in” of AI monotherapy prior to definitive surgery. Premenopausal women were given GNRH agonist treatment 2 W prior to AI therapy. FLT PET was performed before AI therapy, and 1-7 days before surgery. Ki-67 was measured in baseline core biopsy and surgical specimens.

Results: Fourteen patients (8 postmenopausal, 6 premenopausal) have been enrolled. All have undergone baseline FLT PET imaging; 11 have completed imaging and surgery, including one premenopausal patient with no residual invasive carcinoma following 26 days of AI therapy. The majority harbored ductal carcinomas (n = 9, 5 with lobular histology) with the majority histologic grade ≥ 2 (n = 11). The median number of days exposed to AI was 19 (range, 9-42). Baseline SUVmax ranged from 1.2 to 3.9 (median 2.2), and post run-in SUV (6-64 days later) ranged from 1.2 to 2.8 (median 1.8). Baseline Ki-67 ranged from 6-26.2, median 11.6; surgical Ki-67 post AI therapy ranged from 0- 20.3 median 3.7, with seven below 5%. SUV and flux declined in most patients, as did Ki-67.

Quantitative FLT flux correlated with tumor response assessed by proliferative index (Ki-67) before the “run-in” period, with a stronger correlation at surgery, Pearson correlation coefficients = 0.41 and 0.82, respectively. FLT SUV and qualitative changes were not strongly associated with Ki-67.

Conclusions: Both pre and postmenopausal women with early stage breast cancer showed imaging and tissue response to endocrine therapy. Quantitative, but not qualitative FLT is a promising tool to assess tumor proliferation and response to therapy. Accrual is ongoing and updated results will be reported.

Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-01-02.

Inter-seasonal population dynamics and pest status of Bemisia tabaci (Gennadius) biotype B in an Australian cropping system

Bemisia tabaci, biotype B, commonly known as the silverleaf whitefly (SLW) is an alien species that invaded Australia in the mid-90s. This paper reports on the invasion ecology of SLW and the factors that are likely to have contributed to the first outbreak of this major pest in an Australian cotton cropping system. Population dynamics of SLW within whitefly-susceptible crop (cotton and cucurbit) and non-crop vegetation (sowthistle, Sonchus spp.) components of the cropping system were investigated over four consecutive growing seasons (September-June) 2001/02-2004/05 in the Emerald Irrigation Area (EIA) of Queensland, Australia. Based on fixed geo-referenced sampling sites, variation in spatial and temporal abundance of SLW within each system component was quantified to provide baseline data for the development of ecologically sustainable pest management strategies. Parasitism of large (3rd and 4th instars) SLW nymphs by native aphelinid wasps was quantified to determine the potential for natural control of SLW populations. Following the initial outbreak in 2001/02, SLW abundance declined and stabilised over the next three seasons. The population dynamics of SLW is characterised by inter-seasonal population cycling between the non-crop (weed) and cotton components of the EIA cropping system. Cotton was the largest sink for and source of SLW during the study period. Over-wintering populations dispersed from weed host plant sources to cotton in spring followed by a reverse dispersal in late summer and autumn to broad-leaved crops and weeds. A basic spatial source-sink analysis showed that SLW adult and nymph densities were higher in cotton fields that were closer to over-wintering weed sources throughout spring than in fields that were further away. Cucurbit fields were not significant sources of SLW and did not appear to contribute significantly to the regional population dynamics of the pest. Substantial parasitism of nymphal stages throughout the study period indicates that native parasitoid species and other natural enemies are important sources of SLW mortality in Australian cotton production systems. Weather conditions and use of broad-spectrum insecticides for pest control are implicated in the initial outbreak and on-going pest status of SLW in the region.

18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC)

e15037

Background: Information on the prognostic and predictive role of FDG-PET in the management of patients (pts) with mCRC is limited. The growing complexity of current therapies and the increasing number of agents to be tested in this disease warrants better understanding of the role of FDG-PET in earlier treatment decisions. Methods: Consecutive pts with 2 or more serial FDG-PET scans at baseline and during the treatment course were studied. Tumor standardized uptake value (SUV) and its percentage change (%ΔSUV) were each studied for their potential association with time to progression (TTP) via univariate Cox models to estimate the hazard ratio (HR) for progression. Results: 27 pts (median age 58.2 yrs) with mCRC were studied. 85% of pts were treated in the first line setting. 44% had received prior adjuvant therapy. 63%, 26% and 11% received oxaliplatin based, irinotecan based and fluropyrimidine only regimens, respectively. 85% received concurrent bevacizumab. Median pretreatment SUV was 9.0 (range 1.7 - 46.0); Median post treatment SUV was 3.4 (0–13.5); median %ΔSUV was -77.2 (range -10% to -100%). Mean interval between scans was 4.1 months. Ten (37%) patients had no tumor uptake on post treatment scans. 56% and 37% of pts had partial response and stable disease (RECIST criteria), respectively. Median TTP was 13.0 months (90% CI: 10.9 - 16.3 mos), with a median follow-up time for progression of 7.8 months. The HRs for baseline SUV and %ΔSUV were 0.972 (90% CI: 0.901 - 1.048, p=0.534) and 1.018 (90% CI: 1.003 - 1.033, p=0.049), respectively. The median TTP of patients whose post-treatment SUV reached zero was 13.8 months vs. 10.9 months (p=0.17) for pts whose post-treatment SUV did not reach zero. Conclusions: Systemic therapy significantly decreased the SUV on follow up PET scans in pts treated for mCRC. However, no significant association was seen between either baseline SUV or %ΔSUV and TTP. There may be a very weak statistical association of decreasing SUV with decreasing risk of progression. Further work is needed to optimize and standardize evaluation of tumor response in mCRC patients with FDG-PET.

No significant financial relationships to disclose.

A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer

4563

Background: VEGF (vascular endothelial growth factor) has a central role in angiogenesis, tumor growth and metastasis of gastric cancer. Bevacizumab, an anti-VEGF monoclonal antibody, has demonstrated anti-tumor activity in multiple diseases. This phase II study was undertaken to determine the effects of adding bevacizumab to a regimen of docetaxel and oxaliplatin. Methods: The primary endpoint was time to progression (TTP) in patients with locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction treated with docetaxel, oxaliplatin and bevacizumab. Previously untreated patients with a performance status (PS) of 0–1 were eligible for this study. Patients received bevacizumab 7.5 mg/kg, docetaxel 70 mg/m2 and oxaliplatin 75 mg/m2 administered on day 1 of a 21 day cycle. Results: A total of 23 patients (median age 57, males 70%, gastric 52%) were enrolled on the study. Median PS was 1. The median number of cycles was 5. Ten patients are still receiving treatment on study. Partial responses were documented in 10 (59%) patients and stable disease in 7 (41%). No treatment related deaths were observed. The most commonly reported grade 3–4 toxicities were neutropenia (13%), leukopenia (4%), fever (4%), acute neuropathy (4%), and hypertension (4%). Gastrointestinal (GI) perforation occurred in 3 patients. Perforation was not found at the tumor site in the patient who required surgery. The site of perforation could not be ascertained in the second patient who was managed medically. Both patients had had no prior surgical resection of the primary tumor. The third perforation presented as a tracho-bronchial fistula. The patient had previously undergone surgical resection of his primary tumor after receiving chemoradiotherapy to the thoracic area. Conclusions: The regimen of docetaxel, oxaliplatin and bevacizumab appears to be very active. The development of GI perforations in 3 patients is of concern. At this time, bevacizumab should not be used in gastric or gastroesophageal junction cancers outside of a clinical trial until its safety is well established.

[Table: see text]

Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC)

e19007

Background: There are only limited data regarding the use of anti-VEGF therapy in recurrent NSCLC and no data in NSCLC pts previously treated with bevacizumab. We are currently conducting a phase II trial evaluating cediranib, an oral inhibitor of VEGFR 1,2 and 3, and pemetrexed in recurrent NSCLC pts who may or may not have previously received bevacizumab. Methods: Pts with progressive and measurable NSCLC, 1 or 2 prior regimens, PS0–2, all histologic sub-types, BP ≤ 140/90, treated brain metastases are eligible. Pts on anti-coagulants are allowed. Pts with hemorrhage within 4 weeks are excluded. Pts start on cediranib 30mg daily followed 7 days later by pemetrexed at 500 mg/m2 every 21 days and cediranib daily. The study consists of two cohorts- cohort A (no prior bevacizumab) and cohort B (prior bevacizumab). Planned accrual is 37 pts each cohort. Consenting pts will undergo FLT PET scans and blood draw for circulating tumor cells before therapy, 1 week after cediranib, and after 1 cycle of the combination. Results: 33 pts have started therapy, (Cohort A- 20, Cohort B- 13), median age- 60, males- 56%, ever smokers- 88%, adenocarcinoma- 64%, squamous- 12%, brain mets- 27%, 1 prior regimen- 52%, PS0–1- 88%. Median cycles- 4 (range- 0–15). Grade 3/4 toxicities- neutropenia- 7pts, febrile neutropenia- 1pt, fatigue-7pts, diarrhea- 3pts, hypertension- 1pt, anorexia- 2pts, cardiac ischemia- 1pt, bronchopleural fistula- 1pt, esophagitis- 1pt. No major hemorrhage. Of the 17 pts who received cediranib for ≥ 4 cycles, 71% required dose reduction and of the 18 pts who received pemetrexed for ≥ 4 cycles, 22% required dose reduction. 31 pts (Cohort A- 19, Cohort B- 12) are response evaluable. Confirmed response rate is 16%(90% CI- 0.08–0.30) (Cohort A- 10%, Cohort B- 25%) and disease control rate (response+stable disease) is 71% (90% CI-0.56–0.82) (Cohort A- 74%, Cohort B- 67%). 8 of 9 pts who had FLT PET scans had a 20% or greater decline in standard uptake value after 1 week of cediranib alone. Conclusions: Cediranib and pemetrexed combination is tolerable. Efficacy has been observed with the combination in recurrent NSCLC pts, including those previously treated with bevacizumab. Accrual to this trial is ongoing.

[Table: see text]

Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors

3034

Background: AZD2171 is an oral, potent, selective inhibitor of vascular endothelial growth factor receptor (VEGFR). Trials have demonstrated that inhibition of the VEGF pathway, in combination with certain chemotherapy, provides benefit to patients with a broad range of solid tumors. Methods: This Phase I trial was conducted in heavily pretreated solid tumor patients. In a single protocol, escalating doses of AZD2171 were evaluated (20, 30 and 45 mg) in combination with four separate chemotherapy regimens: mFOLFOX6 (oxaliplatin 85 mg/m2; 5-FU 400 mg/m2; leucovorin 400 mg/m2 q2 weeks; Arm 1); irinotecan 300 mg/m2 q3 week (Arm 2); docetaxel 75 mg/m2 (Arm 3) and pemetrexed 500 mg/m2 (Arm 4). The primary objective was to evaluate safety and tolerability of the combinations and secondary objective to evaluate pharmacokinetic (PK) interaction and clinical efficacy. Maximum tolerated dose (MTD) toxicity was defined through two cycles. Results: 46 patients have been enrolled: 28/35 evaluable for efficacy/toxicity. The MTD has been reached in two arms: Arm 2 - 20 mg AZD2171 and Arm 4 - 30 mg AZD2171. Arm 3 enrollment continues at 45 mg AZD2171. Two dose-limiting toxicities (DLTs) were observed in eight patients at 30 mg AZD2171 in Arm 1. Enrollment of an additional cohort of less heavily pre-treated patients is ongoing to determine the tolerability of 30 mg AZD2171 with FOLFOX. DLTs have included grade 3 fatigue in Arms 1, 2 & 4; grade 3 diarrhea in Arm 1; grade 3 hand-foot syndrome & grade 4 neutropenic fever in Arm 2; and grade 3 hypertension in Arm 4. AZD2171 did not appear to have a major effect on the PK profile of any chemotherapy regimen tested. Steady-state values are comparable with AZD2171 monotherapy. There have been 13 responses (minor response, n=5; partial response, n=6; complete response, n=2; stable disease ≥ 4 cycles, n=6) in heavily pretreated patients, some having demonstrated resistance to identical chemotherapies. Duration of response has been impressive (4-22+ cycles). Conclusions: AZD2171 combinations have been well tolerated with expected toxicities and encouraging responses.

[Table: see text]